Evidence map›Paper›PMID 38819167›Full record

ArticleJournal of clinical microbiology2024

Azole resistance screening in

Julia Serrano-Lobo, Elena Reigadas, Patricia Muñoz, Pilar Escribano, Jesús Guinea, ASPEIN Study Group

Abstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Detection of TR34/L98H pan-azole-resistantFrontiers in fungal biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julia Serrano-LoboClinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID 0000-0003-4537-6549
Elena ReigadasClinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Patricia MuñozClinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Pilar Escribano *Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID 0000-0001-6254-4570
Jesús Guinea *Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID 0000-0002-7901-8355
ASPEIN Study Group

Funding

Fondo de Investigación Sanitaria PI21/00450Gilead Sciences (Gilead)
6 · The paper itself

Abstract

Azole resistance screening in IMPORTANCE: Azole resistance screening in

Indexed as

Antifungal AgentsAspergillus fumigatusAzolesDrug Resistance, FungalMicrobial Sensitivity TestsSpores, FungalAgarCulture MediaCytochrome P-450 Enzyme SystemFungal ProteinsHumansAgarAntifungal AgentsAzolesCulture Mediacytochrome P-450 CYP51A, AspergillusCytochrome P-450 Enzyme SystemFungal ProteinsAspergillus fumigatusazole-containing platesazole resistancedetectionE.Def 10.2EUCAST

Identifiers

PMID38819167
PMCPMC11250424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.